Abstract
The perceptible decrease in the incidence of breast cancer in recent years has not influenced its societal and economic impact and it remains as the most commonly diagnosed malignancies among females. Recent reports of clinical trials in preventive settings suggested chemoprevention as an appealing strategy zeroing heavily on endocrine intervention using selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). Unfortunately, these drugs are only effective in prevention of endocrine responsive lesions with essentially no effect in reducing the risk of estrogen-negative breast cancer. Further, the existing drugs for breast cancer treatment are invariably associated with several drawbacks such as poor oral bioavailability, non-selectivity and poor pharmacodynamics properties, limiting their clinical utility. Thus, the identification of new molecular targets and the development of agents with better pharmacological profiles will streamline the development of rational, effective and safe anticancer drugs with minimal side-effects. Over the past few years, different research groups have been actively involved in the design and synthesis of novel anti-breast cancer agents. In this review article, the recent developments (2013 onwards) made in the direction of synthesis of new scaffolds with promising anti-breast cancer activity, are briefly described. Hopefully, the data compiled in this article will update scientific community with recent endeavors in this field, and will certainly be encouraging for further research in this direction.
Keywords: Breast cancer, heterocyclic scaffolds, single pharmacophore based agents, multiple pharmacophore based agents, molecular modifications.
Anti-Cancer Agents in Medicinal Chemistry
Title:A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Volume: 16 Issue: 6
Author(s): Parvesh Singh, Nomandla Ngcoya and Vipan Kumar
Affiliation:
Keywords: Breast cancer, heterocyclic scaffolds, single pharmacophore based agents, multiple pharmacophore based agents, molecular modifications.
Abstract: The perceptible decrease in the incidence of breast cancer in recent years has not influenced its societal and economic impact and it remains as the most commonly diagnosed malignancies among females. Recent reports of clinical trials in preventive settings suggested chemoprevention as an appealing strategy zeroing heavily on endocrine intervention using selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). Unfortunately, these drugs are only effective in prevention of endocrine responsive lesions with essentially no effect in reducing the risk of estrogen-negative breast cancer. Further, the existing drugs for breast cancer treatment are invariably associated with several drawbacks such as poor oral bioavailability, non-selectivity and poor pharmacodynamics properties, limiting their clinical utility. Thus, the identification of new molecular targets and the development of agents with better pharmacological profiles will streamline the development of rational, effective and safe anticancer drugs with minimal side-effects. Over the past few years, different research groups have been actively involved in the design and synthesis of novel anti-breast cancer agents. In this review article, the recent developments (2013 onwards) made in the direction of synthesis of new scaffolds with promising anti-breast cancer activity, are briefly described. Hopefully, the data compiled in this article will update scientific community with recent endeavors in this field, and will certainly be encouraging for further research in this direction.
Export Options
About this article
Cite this article as:
Singh Parvesh, Ngcoya Nomandla and Kumar Vipan, A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (6) . https://dx.doi.org/10.2174/1871520616666151120122120
DOI https://dx.doi.org/10.2174/1871520616666151120122120 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Opioid Free Anaesthesia and Cancer
Current Pharmaceutical Design Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Effect of the External Electric Field on the Structure and Reactivity of Model Complex Lipids
Current Physical Chemistry Gene Expression Studies in Multiple Sclerosis
Current Genomics Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Protein & Peptide Letters The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology ADDENDUM: Nutraceuticals for Protection and Healing of Gastrointestinal Mucosa. Romano M, Vitaglione P, Sellitto S, D’Argenio G. Curr Med Chem 2012, 19: 109-117.
Current Medicinal Chemistry Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
Current Drug Delivery Editorial [Hot Topic:Novel Targets in Cancer Therapy(Guest Editor: Debabrata Banerjee)]
Current Pharmaceutical Biotechnology The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise
Current Pharmaceutical Design Suppression of TLR Signaling by Targeting TIR domain-Containing Proteins
Current Protein & Peptide Science Targeting p53 in Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008
Current Pharmacogenomics and Personalized Medicine Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry